Blog

Mar 21, 2018

Anyone Can Now Take This Breast Cancer Gene Test, But It Probably Won’t Tell You Much

Posted by in categories: biotech/medical, genetics

Breast and ovarian cancers are scary, anxiety-provoking diseases, and with good reason. Although breast cancer isn’t the cancer that kills the most women (lung cancer holds that distinction), it is the most commonly diagnosed cancer in women. And ovarian cancer is difficult to find in its early stages. But anyone willing to spit in a tube and pay $199 will soon be able to find out if they have a particular genetic predisposition to either of these cancers.

This month, the FDA granted the genetics company 23andMe permission to offer direct-to-consumer testing for three of the more than 1,000 known variants of the genes BRCA1 and BRCA2The variants may also boost the risk of prostate cancer and melanoma.

Read more

Comments are closed.